Category - News

Markets

Ladenburg starts ContraFect at buy; PT $3

Ladenburg Thalmann initiated coverage of ContraFect (NASDAQ:CFRX) with a “buy” rating and $3 price target. The stock closed at $2.59 on July 9. “We view ContraFect as a biologics story with a potential first-in-class...

July 10, 2018

Markets

Roth starts Kalvista Pharma at buy; PT $20

Roth Capital Partners launched coverage of Kalvista Pharmaceuticals (NASDAQ:KALV) with a “buy” rating and price target of $20. The stock closed at $8.82 on July 9. Analyst Jotin Marango writes that behind its cultivated...

July 10, 2018

Markets

HCW starts RXi Pharma at buy; PT $3

H.C. Wainwright launched coverage of RXi Pharmaceuticals (NASDAQ:RXII) with a “buy” rating and price target of $3. The stock closed at $1.97 on July 6. RXi is focused on improving the efficiency and anti-tumor activity...

July 9, 2018

Developments

IntelGenx receives Canadian patent notice for Loxapine VersaFilm

The Canadian Intellectual Property Office (“CIPO”) has issued a notice of allowance for IntelGenx’s (TSXV:IGX; OTCQX:IGXT) first Canadian patent application for its VersaFilm technology. Entitled, “Loxapine Film Oral...

July 5, 2018

Markets

Leerink cuts Epizyme to market perform and PT to $16

Leerink downgraded Epizyme (NASDAQ:EPZM) to “market perform” from “outperform” and lowered its price target to $16 from $24 after making extensive changes to its revenue forecasts for Epizyme’s only drug, tazemetostat...

July 3, 2018

Developments

ASLAN Pharma applies for first-in-man study of ASLAN004

ASLAN Pharmaceuticals (TPEx:6497; NASDAQ:ASLN) has applied to the Singapore Health Sciences Authority to conduct a Phase 1 clinical trial of ASLAN004. The single ascending dose study will recruit healthy volunteers and...

July 3, 2018

Markets

HCW starts Celyad at buy; PT $45

H.C. Wainwright initiated coverage of Celyad (NASDAQ:CYAD) with a “buy” rating and $45 price target, citing the outlook of the company’s pipeline that includes lead candidate, CYAD-01. The stock closed at $30.99...

July 2, 2018

Markets

Neuronetics prices IPO at $17 a share

Neuronetics (NASDAQ:STIM) priced its initial public offering of 5.5 million shares common shares at $17 each. The company also granted underwriters a 30-day option to purchase up to an additional 825,000 shares at the...

June 29, 2018

Markets

Maxim cuts Keryx Biopharmaceuticals to hold on merger plans

Maxim Group downgraded Keryx Biopharmaceuticals (NASDAQ:KERX) to “hold” from “buy” and removed its price target after Keryx and Akebia Therapeutics (NASDAQ:AKBA) unveiled a definitive agreement to merge in an all-stock...

June 28, 2018

Markets

HCW starts AquaBounty at buy; PT $3.75

H.C. Wainwright launched coverage of AquaBounty Technologies (NASDAQ:AQB) with a “buy” rating and a “conservative” $3.75 price target. The stock closed at $2.99 on June 27. AquaBounty is focused on enhancing...

June 28, 2018

Category - News

Subscribe